Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells.

Peyrusson, Frédéric;Van Wessem, Astrid;Dieppois, Guennaëlle;Van Bambeke, Françoise;Tulkens, Paul M
(2020) International Journal of Antimicrobial Agents — Vol. 55, n° 2, p. 105848 (2020)

Files

Peyrusson-2020-1.pdf
  • Open Access
  • Adobe PDF
  • 1.51 MB
Download

Details

Authors
  • Peyrusson, FrédéricUCLouvain
    Author
  • Van Wessem, AstridUCLouvain
    Author
  • Dieppois, Guennaëlle
    Author
  • Van Bambeke, FrançoiseUCLouvain
    Author
  • Tulkens, Paul MUCLouvain
    Author
Abstract
Antibiotics with new modes of action that are active against intracellular forms of Staphylococcus aureus are sorely needed to fight recalcitrant infections caused by this bacterium. Afabicin desphosphono (Debio 1452, the active form of afabicin [Debio 1450]) is an inhibitor of FabI enoyl-Acyl carrier protein reductase and has specific and extremely potent activity against Staphylococci, including strains resistant to current antistaphylococcal agents. Using mouse J774 macrophages and human THP-1 monocytes, we showed that afabicin desphosphono: (i) accumulates rapidly in cells, reaching stable cellular-to-extracellular concentration ratios of about 30; (ii) is recovered entirely and free in the cell-soluble fraction (no evidence of stable association with proteins or other macromolecules). Afabicin desphosphono caused a maximum cfu decrease of about 2.5 log after incubation in broth for 30 h, including against strains resistant to vancomycin, daptomycin, and/or linezolid. Using a pharmacodynamic model of infected THP-1 monocytes (30 h of incubation post-phagocytosis), we showed that afabicin desphosphono is bacteriostatic (maximum cfu decrease: 0.56 to 0.73 log) towards all strains tested, a behaviour shared with the comparators (vancomycin, daptomycin, and linezolid) when tested against susceptible strains. We conclude that afabicin desphosphono has a similar potential as vancomycin, daptomycin or linezolid to control the intracellular growth and survival of phagocytized S. aureus and remains fully active against strains resistant to these comparators.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Peyrusson, F., Van Wessem, A., Dieppois, G., Van Bambeke, F., & Tulkens, P. M. (2020). Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells. International Journal of Antimicrobial Agents, 55(2), 105848. https://doi.org/10.1016/j.ijantimicag.2019.11.005 (Original work published 2020)